Shares of health-care companies rose as traders bet the sector would benefit from the outcome of Senate negotiations on the health-care bill. There were also hints earlier in the week of a more expedited approach to Food and Drug Administration approval processes emerging under new leadership. Shares of Johnson & Johnson rose after the drug giant received approval for a psoriasis product, which will come with a hefty price tag. Mylan ticked up after the FDA approved its generic version of Roche Holdings' breast cancer drug Herceptin.
-Rob Curran, firstname.lastname@example.org
Continue Reading Below
(END) Dow Jones Newswires
July 14, 2017 16:21 ET (20:21 GMT)